---
title: "SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD 0.26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240061822.md"
datetime: "2025-05-13T20:52:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240061822.md)
  - [en](https://longbridge.com/en/news/240061822.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240061822.md)
---

# SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD 0.26

EPS: As of FY2025 Q1, the actual value is USD 0.26.

EBIT: As of FY2025 Q1, the actual value is USD -1.735 M.

### Segment Revenue

-   **Research and Development Expenses**: $590,000 for the three months ended March 31, 2025, compared to $961,000 for the same period in 2024, representing a decrease of 40%.
-   **General and Administrative Expenses**: $1,060,000 for the three months ended March 31, 2025, compared to $289,000 for the same period in 2024, representing an increase of 266.7%.

### Operational Metrics

-   **Net Loss**: $1,735,000 for the three months ended March 31, 2025, compared to $1,423,000 for the same period in 2024, an increase of 21.4%.
-   **Operating Loss**: $1,650,000 for the three months ended March 31, 2025, compared to $1,250,000 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $2,453,000 for the three months ended March 31, 2025, compared to - $1,752,000 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $7,432,000 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.

### Unique Metrics

-   **Cash and Cash Equivalents**: $6,233,000 as of March 31, 2025, compared to $2,831,000 as of March 31, 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue investing in the development of SIL204, including applying for Orphan Drug Designation in the U.S. and EU, conducting toxicological studies, and initiating clinical trials.
-   **Non-Core Business**: The company is exploring additional product candidates to add to its pipeline and plans to expand its intellectual property portfolio.

### Related Stocks

- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [1 Unstoppable Stock to Buy Before It Joins Nvidia, Alphabet, Apple, and Microsoft in the $3 Trillion Club](https://longbridge.com/en/news/287021527.md)
- [Goldman Sachs set to be named lead left underwriter for SpaceX IPO, source says](https://longbridge.com/en/news/286975906.md)
- [SanDisk stock slips: why this analyst still sees a 50% upside](https://longbridge.com/en/news/286938149.md)
- [Market Chatter: Intel Urges PC Makers to Adopt Advanced CPUs Amid Supply Crunch](https://longbridge.com/en/news/286955059.md)
- [EXCLUSIVE: Google's AI Monetization Strategy May Be Leaving Rivals Behind, Says Direxion](https://longbridge.com/en/news/286919559.md)